Nicardipine implant - BIT pharma
Alternative Names: NicaPlantLatest Information Update: 21 Jul 2023
At a glance
- Originator BIT Pharma
- Class Amines; Antihypertensives; Dihydropyridines; Ischaemic heart disorder therapies; Nitrobenzenes; Small molecules
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Subarachnoid haemorrhage
Most Recent Events
- 28 Nov 2022 Phase II development is still ongoing for Subarachnoid haemorrrhage (In adults, In the elderly) in Austria and Germany (Intracerebral, Implant) (NCT04269408)
- 13 Feb 2020 BIT Pharma initiates a phase II trial in Subarachnoid haemorrrhage (In adults, In the elderly) in Austria (Intracerebral, Implant) (NCT04269408)
- 27 Dec 2019 Nicardipine implant - BIT pharma receives Orphan Drug status for Subarachnoid haemorrhage in Europe